Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

This study has been completed.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Intraocular Melanoma
			Melanoma (Skin)
2		Additional conditions recognized in this trial
			Eye Neoplasms
			Melanoma
3		More general conditions related to this trial
			Eye Diseases
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Neoplasms, Germ Cell and Embryonal
			Neoplasms, Nerve Tissue
			Neuroectodermal Tumors
			Neuroendocrine Tumors
			Nevi and Melanomas
4		Interventions listed in this trial
			MART-1 antigen
			alum adjuvant
			gp100 antigen
			incomplete Freund's adjuvant
			recombinant interleukin-12
			sargramostim
			tyrosinase peptide
			adjuvant therapy
5		Additional drug interventions recognized in this trial
			Aluminum sulfate
			Freund's Adjuvant
			Interleukin-12
6		More general drug interventions related to this trial
			Adjuvants, Immunologic
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Antineoplastic Agents
			Growth Inhibitors
			Growth Substances
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			Norris Comprehensive Cancer Center
			National Cancer Institute (NCI)